Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 6/20 | 0.38 |
| ▸ | PYGL | P06737 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037227 | 0.72 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2PYGMPYGLLMNA | |
| SCHEMBL9797407 | 0.70 | GAA (0.46) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL2699668 | 0.62 | PYGM (0.33) | PYGMPYGLLMNA | |
| SCHEMBL2853254 | 0.59 | F2 (0.57) | ALDH1A1LMNA | |
| SCHEMBL10336238 | 0.58 | F2 (0.42) | ALDH1A1LMNARECQLMEN1KMT2A | |
| SCHEMBL2701387 | 0.57 | L3MBTL1 (0.34) | — | |
| SCHEMBL9812716 | 0.55 | FFAR3 (0.36) | — | |
| SCHEMBL15825651 | 0.53 | F2 (0.48) | ALDH1A1LMNAHTT | |
| SCHEMBL19103223 | 0.53 | F2 (0.35) | ALDH1A1LMNA | |
| SCHEMBL14275464 | 0.53 | F2 (0.48) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248457-B | Substrate for synthesizing beta-Se amino acid, and preparation method and application thereof | 上海交通大学 | 2024-05-17 | — | — | CN | claimed |
| CN-117623925-A | Method for deoxidizing and converting photocatalytic alcohol | 同济大学 | 2024-03-01 | — | — | CN | claimed |
| CN-117304081-A | Method for synthesizing homoallylic alcohol compound by synergistic catalysis of visible light and titanium | 河南师范大学 | 2023-12-29 | — | — | CN | claimed |
| CN-117105764-A | Method for preparing cis-15-tetracosenoic acid from erucic acid peroxide | 山东省农业科学院 | 2023-11-24 | — | — | CN | claimed |
| CN-115417759-B | Method for preparing nervonic acid by using erucic acid redox active ester | 山东省农业科学院 | 2023-11-07 | — | — | CN | claimed |
| CN-115974891-B | Preparation method of norcantharidin | 仁和堂药业有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-115007177-B | CdSeS phantom number nanocluster and application thereof as photocatalyst | 四川大学 | 2023-06-23 | — | — | CN | claimed |
| CN-115888841-B | Organic amine coordinated CdSe nano sheet and application thereof as photocatalyst | 四川大学 | 2023-05-30 | — | — | CN | claimed |
| CN-114315894-B | Chiral alpha-aryl phosphate, chiral alpha-aryl phosphine compound and synthesis thereof | 同济大学 | 2023-05-26 | — | — | CN | claimed |
| CN-116023377-A | Preparation method of non-nereirenone and key chiral intermediate thereof | 杭州科巢生物科技有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-116023401-A | Preparation method of chiral borate compound | 同济大学 | 2023-04-28 | — | — | CN | claimed |
| WO-2025056065-A1 | CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE | 上海医药集团股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-114292304-B | Method for synthesizing aryl alkyne lead compound | 康龙化成(宁波)科技发展有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118234734-A | Pyrimidine tricyclic derivatives and their use in medicine | 正大天晴药业集团股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113248457-B | Substrate for synthesizing beta-Se amino acid, and preparation method and application thereof | 上海交通大学 | 2024-05-17 | — | — | CN | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
| US-6288096-B1 | ANTIDIABETIC AGENTS, HYPOTENSIVE AGENTS, AND ANTICHOLESTEROL AGENTS | ASTRAZENECA AB (SE) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | ALDH1A1 1255/4885SMN1; SMN2 2155/4885PYGM 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.